Follow Viking Therapeutics to never miss an important update.
Viking shared data from two of its weight-loss drug trials at the ObesityWeek conference. The presentations covered the starting health profiles of patients in its latest Phase 3 study and how its lead drug, VK2735, affected heart health and obesity severity in an earlier Phase 2 trial. While these presentations are a routine part of the drug development process, they keep the medical community focused on Viking's progress. For a company with no products on the market yet, every update from these trials helps build the case that its treatment is both safe and effective compared to existing injections.
Source: PRNewsWire
Viking reported a loss of $1.55 per share, which was wider than the $1.06 loss analysts expected. For a biotech company with no products on the market, these quarterly losses are normal as they spend heavily on research. The more important number is its cash pile, which grew to $960 million. This gives the company a long runway to finish its expensive clinical trials without needing to borrow money soon.
The company also reached a key milestone by starting its Phase 3 trial for the oral version of its obesity drug. This is a critical part of the business plan, as a daily pill could be much more popular than the weekly injections currently sold by rivals. While the financial loss was larger than expected, the progress in its drug pipeline and the strengthened cash position keep the company on a steady path toward getting its first product approved.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
After Viking Therapeutics reported its October results, we updated our fair value and our quality score to 3.7. We added the company's $960 million cash pile to what we track, which is enough money to finish the final round of drug trials. We also started tracking whether patients can keep weight off using doses just once a month, which would be a competitive edge over rivals. We have added a second potential obesity drug that uses a different biological mechanism to our projections.
Viking Therapeutics reports its quarterly results today. Because the company is still in the clinical-stage, meaning it is testing drugs but does not have any for sale yet, it generates no revenue. Analysts expect a loss of about $1.06 per share as the company spends cash to run its trials.
The numbers themselves matter less than the update on its obesity drug, VK2735. We are watching for any news on the progress of its Phase 3 trials and the development of its oral version, which could be a major advantage over the injections currently sold by rivals. With about 603 million dollars in cash at the start of the year, the company has a long runway to fund these tests, but any change in that timeline is the key thing to watch.
Viking will report its quarterly results on October 28, with analysts expecting a loss of about $1.06 per share. Because the company is still in the testing phase and has no products for sale yet, it does not earn any revenue. The focus for the business remains on its cash levels and the progress of its obesity drug trials. This update will be a chance to hear from management about the timeline for its final-stage testing and how much cash it has left to fund its research.
Viking almost always spends more on research than analysts expect, which is normal for a company racing to finish final drug trials. Management is focused on the science rather than hitting quarterly profit targets.
| Expectation | |
|---|---|
| EPS | $-1.38 |
| Revenue | — |
Follow Viking Therapeutics to get the latest and most important updates.
Follow VKTX